Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability.

Area of Science:

• Neuroscience
• Biomaterials Science
• Pharmacology

Background:

• Alzheimer disease (AD) is a leading cause of dementia, characterized by amyloid-beta plaques and neuronal loss.
• Current treatments for AD are limited, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the therapeutic potential of graphene quantum dots conjugated with glycine-proline-glutamate (GQDG) for Alzheimer disease.
• To evaluate GQDG's effects on amyloid-beta aggregation, cognitive function, neurogenesis, and inflammation in a mouse model of AD.

Main Methods:

• In vitro assays (ThT, CD) to assess Aβ1-42 fibril aggregation inhibition.
• Morris water maze test to evaluate learning and memory in APP/PS1 transgenic mice.
• Immunohistochemistry and DiI staining to assess neurogenesis and dendritic spines.
• Suspension array and ELISA to measure inflammatory cytokines and amyloid-beta levels.

Main Results:

• GQDG significantly inhibited Aβ1-42 fibril aggregation in vitro.
• GQDG treatment reduced amyloid plaque burden, enhanced learning and memory, and increased dendritic spine density in APP/PS1 mice.
• GQDG modulated inflammatory responses by decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines.

Conclusions:

• GQDG demonstrates significant neuroprotective effects against Alzheimer disease pathology in a preclinical model.
• GQDG shows promise as a novel therapeutic agent for neurodegenerative diseases like Alzheimer disease.